IDEAYA Biosciences Enters Material Definitive Agreement

TL;DR

IDEAYA signed a big deal, details TBD.

AI Summary

IDEAYA Biosciences, Inc. entered into a material definitive agreement on August 29, 2025. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but it is classified under Item Information as an 'Entry into a Material Definitive Agreement'.

Why It Matters

This filing indicates a significant new contract or partnership for IDEAYA Biosciences, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the material definitive agreement.

Key Players & Entities

• IDEAYA Biosciences, Inc. (company) — Registrant
• August 29, 2025 (date) — Date of earliest event reported
• 5000 Shoreline Court, Suite 300 (address) — Principal executive offices
• South San Francisco, California 94080 (address) — Principal executive offices
• (650) 443-6209 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
• $210 million — ovide the Company an upfront payment of $210 million. The Company is also eligible to receiv
• $100 m — stone payments of up to an aggregate of $100 million, commercial milestone payments of
• $220 m — stone payments of up to an aggregate of $220 million, clinical trial cost sharing and

Filing Documents

• d800731d8k.htm (8-K) — 26KB
• 0001193125-25-193238.txt ( ) — 138KB
• idya-20250829.xsd (EX-101.SCH) — 3KB
• idya-20250829_lab.xml (EX-101.LAB) — 18KB
• idya-20250829_pre.xml (EX-101.PRE) — 11KB
• d800731d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This report contains forward-looking statements, including, but not limited to, statements related to the Company's anticipation that its cash, cash equivalents, and marketable securities, together with the upfront payment and expected cost saving from the Agreement, will fund planned operations into 2030 and provide the Company with a cash runway extension of at least twelve months. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the Company's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, and other matters that could affect the Company's ability to fund planned operations. The Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 18, 2025 and any other current and periodic reports filed with the Securities and Exchange Commission.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: September 2, 2025 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR